About Oryn Therapeutics

Decades of Research

Dr. Michael Selsted and his team, known for their research in immunology, discovered host defense peptides called theta defensins. Dr. Selsted has more than 135 publications to his credit and is Professor and Chairman of the Department of Pathology at the Keck School of Medicine of the University of Southern California.

Dr. Selsted and his collaborators discovered that theta defensins have therapeutic properties in preclinical models of human diseases, leading to founding of Oryn Therapeutics which is developing Orynotides as a new class of macrocyclic peptide therapeutics.

Orynotides at Work

Orynotides are engineered analogs of theta-defensins, macrocyclic peptide molecules that occur naturally in some species of primates, but not humans. Exploiting the properties of these nonhuman primate molecules, Oryn is employing a novel retro-evolutionary approach to drug discovery for research and development of new therapeutics for several clinical indications.

Oryn’s lead Orynotide therapeutic candidate ORTD-1 induced long-lasting disease remission in preclinical models of rheumatoid arthritis. ORTD-1 has the potential to arrest disease in RA patients, providing major enhancement in quality of life without risks associated with immunosuppressive drugs currently in use, including many carrying black box warnings. A Phase 1a clinical trial of ORTD-1 demonstrated safety in healthy volunteers, and a Phase 1b trial in patients with stable rheumatoid arthritis was recently launched.

The therapeutic mechanism of ORTD-1 is predicted to be efficacious against lung inflammation that occurs in SARS-CoV-2 infection (COVID-19). In late 2020, the FDA authorized a Phase 1b/2 clinical trial of safety and efficacy of intravenous ORTD-1 in COVID-19 pneumonia which was recently launched.

Orynotides have a range of properties that make them ideal for therapeutic applications.

Learn More About The Therapeutic Applications

Stable, Well-Funded Biotech

Oryn Therapeutics funded its early operations prior to 2015 through investment by its founders and close associates committed to the company’s mission.